MP 157Alternative Names: MP157
Latest Information Update: 25 Mar 2017
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antihypertensives
- Mechanism of Action Angiotensin type 2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertension
Most Recent Events
- 03 Feb 2016 Phase I development is ongoing in Europe
- 10 May 2011 Phase-I clinical trials in Hypertension in Europe (unspecified route)